FDA Awards Fast Track Status to Revalesio’s RNS60 for ALS; Phase 2 Trial Recruiting
News
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Revalesio’s experimental therapy RNS60 for people diagnosed with amyotrophic lateral sclerosis (ALS). A phase 2 trial ... Read more